Larry R Jackson1,2, Bharath Rathakrishnan3, Kristen Campbell4, Kevin L Thomas1,2, Jonathan P Piccini1,2, Tristram Bahnson5, Jonathan A Stiber2, James P Daubert1,3. 1. Duke Clinical Research Institute. 2. Duke University School of Medicine, Durham, North Carolina. 3. Columbia University College of Physicians and Surgeons, New York City, New York. 4. Department of Pharmacy, Duke University Medical Center, Durham, North Carolina. 5. Division of Adult Cardiac Electrophysiology, Duke University Medical Center, Durham, North Carolina.
Abstract
BACKGROUND: Symptomatic sinus node dysfunction (SND) consists of a variety of manifestations, including tachycardia-bradycardia syndrome. Atrial fibrillation (AF) is commonly associated with SND, which complicates the management of both conditions. This paper reviews the epidemiology, pathophysiology, and clinical trial data investigating therapeutic approaches for treatment of patients with both SND and AF. METHODS: The authors reviewed articles published in English describing the epidemiology, pathophysiology, and therapeutic approaches for patients with SND and AF. The search was conducted using PubMed. Keywords included: sick sinus syndrome, sinus node dysfunction, atrial fibrillation, pacing, and pulmonary vein isolation. RESULTS: SND affects up to one in five patients with AF. AF can lead to anatomical and electrophysiological remodeling in both atria, including the region of sinoatrial node. Changes including atrial fibrosis, altered calcium channel metabolism, and transformed gene expression have been demonstrated in patients with AF and SND. Nonrandomized clinical trial data have failed to demonstrate whether any pacing strategy can reduce the risk of AF. Pulmonary vein isolation appears to decrease episodes of tachybrady syndrome and sinus pauses. CONCLUSIONS: SND affects up to one in five patients with AF. The pathophysiological derangements in gene expression, ion channel metabolism, and alterations in myocardial architecture associated with AF may lead to anatomic and electrical changes in the region of the sinoatrial node. Ablation may improve symptoms associated with SND in patients with AF. Future randomized trials are needed to clarify the epidemiology and optimal management of patients with SND and AF.
BACKGROUND: Symptomatic sinus node dysfunction (SND) consists of a variety of manifestations, including tachycardia-bradycardia syndrome. Atrial fibrillation (AF) is commonly associated with SND, which complicates the management of both conditions. This paper reviews the epidemiology, pathophysiology, and clinical trial data investigating therapeutic approaches for treatment of patients with both SND and AF. METHODS: The authors reviewed articles published in English describing the epidemiology, pathophysiology, and therapeutic approaches for patients with SND and AF. The search was conducted using PubMed. Keywords included: sick sinus syndrome, sinus node dysfunction, atrial fibrillation, pacing, and pulmonary vein isolation. RESULTS: SND affects up to one in five patients with AF. AF can lead to anatomical and electrophysiological remodeling in both atria, including the region of sinoatrial node. Changes including atrial fibrosis, altered calcium channel metabolism, and transformed gene expression have been demonstrated in patients with AF and SND. Nonrandomized clinical trial data have failed to demonstrate whether any pacing strategy can reduce the risk of AF. Pulmonary vein isolation appears to decrease episodes of tachybrady syndrome and sinus pauses. CONCLUSIONS: SND affects up to one in five patients with AF. The pathophysiological derangements in gene expression, ion channel metabolism, and alterations in myocardial architecture associated with AF may lead to anatomic and electrical changes in the region of the sinoatrial node. Ablation may improve symptoms associated with SND in patients with AF. Future randomized trials are needed to clarify the epidemiology and optimal management of patients with SND and AF.
Authors: Verena Semmler; Felix von Krogh; Bernhard Haller; Tilko Reents; Felix Bourier; Marta Telishevska; Marc Kottmaier; Marielouise Kornmayer; Stephanie Brooks; Katharina Koch-Büttner; Carsten Lennerz; Amir Brkic; Christian Grebmer; Patrick Blazek; Severin Weigand; Gabriele Hessling; Christof Kolb; Isabel Deisenhofer Journal: Clin Res Cardiol Date: 2018-11-20 Impact factor: 5.460
Authors: Sven Geurts; Martijn J Tilly; Banafsheh Arshi; Bruno H C Stricker; Jan A Kors; Jaap W Deckers; Natasja M S de Groot; M Arfan Ikram; Maryam Kavousi Journal: Clin Res Cardiol Date: 2022-08-13 Impact factor: 6.138